Company news
Tectonic Therapeutic, Inc. news in 2022
Tectonic Therapeutic, Inc.'s news releases, calls and decks from 2022, newest first.
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
December 6, 2022
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
November 7, 2022
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit
November 6, 2022
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 2, 2022
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
October 26, 2022
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
October 17, 2022
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
September 26, 2022
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
September 19, 2022
AVROBIO to Participate in Four Upcoming Investor Conferences in September
August 30, 2022
AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
AVROBIO to Participate in Two Upcoming Investor Conferences in August
July 31, 2022
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
July 12, 2022
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
May 15, 2022
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
May 9, 2022
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
May 2, 2022
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
March 16, 2022
AVROBIO to Present at Two Upcoming Investor Conferences in March
February 28, 2022
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
January 31, 2022
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
January 27, 2022
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
January 26, 2022